Cargando…

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis

Atherosclerosis affects millions of people worldwide. However, the wide variety of limitations in the current therapeutic options leaves much to be desired in future lipid-lowering therapies. For example, although statins, which are the first-line treatment for coronary heart disease (CHD), reduce t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valanti, Eftaxia-Konstantina, Dalakoura-Karagkouni, Katerina, Sanoudou, Despina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313318/ https://www.ncbi.nlm.nih.gov/pubmed/30282955 http://dx.doi.org/10.3390/jpm8040034

Ejemplares similares

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
por: Daniil, Georgios, et al.
Publicado: (2013)

Correction: Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
Publicado: (2014)

Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome
por: Ng, Theodore W. K., et al.
Publicado: (2009)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

Human Serum Amyloid a Impaired Structural Stability of High-Density Lipoproteins (HDL) and Apolipoprotein (Apo) A-I and Exacerbated Glycation Susceptibility of ApoA-I and HDL
por: Cho, Kyung-Hyun
Publicado: (2022)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

The value of the apoB/apoAΙ ratio and the non-HDL-C/HDL-C ratio in predicting carotid atherosclerosis among Chinese individuals with metabolic syndrome: a cross-sectional study
por: Qin, Guangming, et al.
Publicado: (2015)

Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle
por: Dalla-Riva, Jonathan, et al.
Publicado: (2013)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration
por: Chen, Xun, et al.
Publicado: (2009)

Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake
por: Tognon, Gianluca, et al.
Publicado: (2012)

Comparison of apoA-I helical structure and stability in discoidal and spherical HDL particles by HX and mass spectrometry
por: Chetty, Palaniappan Sevugan, et al.
Publicado: (2013)

ApoA-I/HDL Generation and Intracellular Cholesterol Transport through Cytosolic Lipid-Protein Particles in Astrocytes
por: Ito, Jinichi, et al.
Publicado: (2014)

Synchrotron radiation circular dichroism spectroscopy reveals structural divergences in HDL-bound apoA-I variants
por: Giudice, Rita Del, et al.
Publicado: (2017)

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux
por: Nilsson, Oktawia, et al.
Publicado: (2020)

The ratio of HDL-C to apoA-I interacts with free triiodothyronine to modulate coronary artery disease risk
por: Li, Li, et al.
Publicado: (2021)

Protective and therapeutic potentials of HDL and ApoA1 in COVID-19 elderly and chronic illness patients
por: AbdelHafez, Mohamed Aly
Publicado: (2022)

HDL-apoA-II Is Strongly Associated with 1-Year Mortality in Acute Heart Failure Patients
por: Klobučar, Iva, et al.
Publicado: (2022)

The Effects of Rope Training on Lymphocyte ABCA1 Expression, Plasma ApoA-I and HDL-c in Boy Adolescents
por: Ghorbanian, Bahloul, et al.
Publicado: (2013)

Immunochemical Approach for Monitoring of Structural Transition of ApoA-I upon HDL Formation Using Novel Monoclonal Antibodies
por: Kimura, Hitoshi, et al.
Publicado: (2017)

APOA1-75 G to A Substitution Associated with Severe Forms of CAD, Lower Levels of HDL and apoA-I among Northern Indians
por: Chhabra, S., et al.
Publicado: (2005)

ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2017)

Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?
por: Niesor, Eric J.
Publicado: (2015)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

Structural and Functional Changes of Reconstituted High-Density Lipoprotein (HDL) by Incorporation of α-synuclein: A Potent Antioxidant and Anti-Glycation Activity of α-synuclein and apoA-I in HDL at High Molar Ratio of α-synuclein
por: Cho, Kyung-Hyun
Publicado: (2021)

FAMP, a Novel ApoA‐I Mimetic Peptide, Suppresses Aortic Plaque Formation Through Promotion of Biological HDL Function in ApoE‐Deficient Mice
por: Uehara, Yoshinari, et al.
Publicado: (2013)

HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial
por: Blanco-Rojo, Ruth, et al.
Publicado: (2017)

HDL-C/apoA-I Ratio Is Associated with the Severity of Coronary Artery Stenosis in Diabetic Patients with Acute Coronary Syndrome
por: Sun, Lizhe, et al.
Publicado: (2021)

An apoA-I mimetic peptide facilitates off-loading cholesterol from HDL to liver cells through scavenger receptor BI
por: Song, Xuelei, et al.
Publicado: (2009)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

HDL, Atherosclerosis, and Emerging Therapies
por: Hafiane, Anouar, et al.
Publicado: (2013)

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size
por: Kempen, Herman J., et al.
Publicado: (2014)

Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis
por: Fernández-de-Retana, Sofía, et al.
Publicado: (2017)

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)

Sex differences in HDL ApoC-III in American Indian youth
por: Blackett, Piers R, et al.
Publicado: (2012)

ApoD Mediates Binding of HDL to LDL and to Growing T24 Carcinoma
por: Braesch-Andersen, Sten, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r508ikgk7mcnc1l00s9cr9v8nu